Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 6/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22548795 | 0.84 | KMT2A (0.43) | MEP1BFOLH1KMT2AMEN1L3MBTL1 | |
| SCHEMBL2911625 | 0.83 | MEP1B (0.59) | MEP1BBRD4BRD3PARP1AOC3 | |
| Hydrochloric Acid SCHEMBL3863131 | 0.82 | MEP1B (0.57) | MEP1BBRD4BRD3PARP1AOC3 | |
| SCHEMBL8173564 | 0.79 | MEP1B (0.66) | MEP1BBRD4BRD3PARP1AOC3 | |
| SCHEMBL9917357 | 0.77 | PARP1 (0.52) | MEP1BPARP1FOLH1IDH1L3MBTL1 | |
| SCHEMBL22844086 | 0.77 | MEP1B (0.59) | MEP1BBRD4BRD3PARP1AOC3 | |
| SCHEMBL22651797 | 0.75 | HSD17B1 (0.48) | — | |
| SCHEMBL3957425 | 0.75 | TSHR (0.58) | MEP1BBRD4BRD3KMT2AMEN1 | |
| SCHEMBL2108942 | 0.74 | MEP1B (0.59) | MEP1BPARP1FOLH1KMT2AMEN1 | |
| SCHEMBL45866 | 0.74 | PARP1 (0.57) | MEP1BBRD4BRD3PARP1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | MEP1B 2179/4885BRD4 1090/4885BRD3 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.